-
Posted by
Two Blokes Thu at 7:15 AM -
Filed in
Stock
-
1 view
Clinical Readiness Accelerates Across Genflow Biosciences Lead Programs LONDON, UK / ACCESS Newswire / July 24, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is pleased to report key preclinical activities in two of its lead programs. GF-1002 In preparation for a submission for European Clinical Trial Authorisation (CTA), the EU's regulatory equivalent to the U.S. FDA's IND process, Genflow is continuing to advance key development activities.
